PeploBio and IncellDX Partner to Launch the First Long COVID Test in the UK and EU
"Our collaboration with PeploBio marks a pivotal moment in the battle against Long COVID. The incellKINE Long Hauler Index technology enables us to identify a distinctive immunologic profile unique to Long COVID patients, providing a crucial first step for personalised treatment strategies," said Bruce Patterson, M.D., Founder and CEO at IncellDX.
Dr. Nico Lambri, Managing Director at PeploBio said, "Our mission at PeploBio is to drive innovation in diagnostics, and our partnership with IncellDX underscores our commitment to advancing healthcare solutions. The introduction of this test fills a critical gap, empowering healthcare professionals with the tools needed to address the challenges posed by Long COVID."
About PeploBio
PeploBio is an ISO 15189 accredited clinical laboratory, committed to elevating precision medicine and bringing innovative diagnostic solutions to improve patient outcomes.
About IncellDX
IncellDx is a precision medicine company advancing novel diagnostics and prognostics to better understand and treat infectious disease and cancer. The company's innovative technology platform enables simultaneous cell classification and single cell analysis of proteomic and genomic biomarkers.
For media enquiries, please contact:
View original content:https://www.prnewswire.co.uk/news-releases/peplobio-and-incelldx-partner-to-launch-the-first-long-covid-test-in-the-uk-and-eu-302119451.html
